Innovation & Research

Clinical trials database

The information given herein regards the clinical studies conducted by the Menarini Group and is not intended for promotional or marketing purposes, nor is it meant to replace the advice of the physician, who is ultimately responsible for the choice of the most suitable treatment for the individual patient.

Clinical Trials Results


DATASHARING


LOGIN

Oncology Analgesia Cardiovascular & Metabolic Gastrointestinal disorders Respiratory & Allergology Other
Medical Condition
Compound
Phase
Status
Requirements
 
Acute Myeloid Leukemia
SEL24/MEN1703
I/II
Recruiting
≥18 Years
Read More
A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia (DIAMOND-01)
Advanced Solid Tumors
SL-901
I
Recruiting
≥18 Years
Read More
A Phase 1, Open-label, Dose-escalation Study of the PI3K Inhibitor SL-901 in Patients
Chronic Myelomonocytic Leukemia or Myelofibrosis
Tagraxofusp / SL-401
II
Recruiting
≥18 Years
Read More
Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML) or Myelofibrosis (MF)
Colorectal Cancer
MEN1611
I/II
Recruiting
≥18 Years
Read More
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)
Breast Cancer
MEN1611
I
Active not recruiting
≥18 Years
Read More
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer (B-PRECISE-01)
Acute Myeloid Leukemia
MEN1112
I
Terminated
≥18 Years
Read More
First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia (ARMY-1)
Advanced Solid Tumors
Felezonexor / SL-801
I
Terminated
≥18 Years
Read More
A Phase 1 Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors
Ovarian cancer
Abagovomab
II/III
Terminated
≥18 Years
Read More
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (MIMOSA)
Solid Tumors/ Non-Hodgkin Lymphoma
MEN1309
I
Terminated
≥18 Years
Read More
MEN1309 Intravenous Infusion in Patients With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory Non-Hodgkin Lymphoma Phase I Study (CD205-SHUTTLE)

Recruitment status:

NOT YET RECRUTING: The study has not started recruiting participants
RECRUITING: The study is currently recruiting participants.
ACTIVE, NOT RECRUITING: The study is ongoing (that is, participants are receiving an intervention or being examined), but potential participants are not currently being recruited or enrolled.
COMPLETED: The study has ended normally, and participants are no longer being examined or treated (that is, the "last subject, last visit" has occurred).
TERMINATED: The study has stopped recruiting or enrolling participants early and will not start again. Participants are no longer being examined or treated.
WITHDRAWN: The study stopped early, before enrolling its first participant.

precision medicine

Our pipeline and products

Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.

Read More